ADX10059
ADX10059-206
Phase 2 small_molecule terminated
Quick answer
ADX10059 for Migraine is a Phase 2 program (small_molecule) at Addex Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Addex Therapeutics
- Indication
- Migraine
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated